Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith J Chappell

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Plos Pathogens|July 17, 2025
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirusAndrew Young, Sharada Kolekar, Carlos Alvarez Mendoza, et al.
Frontiers in Immunology|June 27, 2022
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 VariantsAriel Isaacs, Alberto A Amarilla, Julio Aguado, et al.
Scientific Reports|February 4, 2017
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgGOleg V Pyankov, Yin Xiang Setoh, Sergey A Bodnev, et al.
Frontiers in Immunology|September 5, 2022
A platform technology for generating subunit vaccines against diverse viral pathogensAndrew Young, Ariel Isaacs, Connor A P Scott, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry|November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Plos Pathogens|July 17, 2025
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirusAndrew Young, Sharada Kolekar, Carlos Alvarez Mendoza, et al.
Frontiers in Immunology|June 27, 2022
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 VariantsAriel Isaacs, Alberto A Amarilla, Julio Aguado, et al.
Scientific Reports|February 4, 2017
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgGOleg V Pyankov, Yin Xiang Setoh, Sergey A Bodnev, et al.
Frontiers in Immunology|September 5, 2022
A platform technology for generating subunit vaccines against diverse viral pathogensAndrew Young, Ariel Isaacs, Connor A P Scott, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry|November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Pageof 6